Clinical Performance and Quality Measures for Adults With Acute ST-Elevation Myocardial Infarction in China
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Quality improvement strategies and tools.
- Who it may be relevant to
- Registry conditions: ST Elevation Myocardial Infarction. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study aims to investigate and evaluate clinical performance and quality measures for adults with acute ST-elevation myocardial infarction (STEMI) in China. Further more, the investigates like to develop quality improvement strategies and relevant tools focusing on treatment and clinical outcome in patients with STEMI. This is a annually survey , through consecutively recruiting all eligible inpatients and collecting relevant medical information, the performance of all participating hospitals. Further, quality improvement strategies including summary of clinical performance and quality measures, clinical pathways and team building will be organized for the purpose of quality improvement. All hospitals will consecutively recruit qualified patients in the same method adopted in baseline period. Then the reperfusion rates and other performance measures will be compared annually.
Detailed description
Cardiovascular disease (CVD) is a major concern in public health globally, as well as in China, and remarkable variations of resources available and health system performance have been noted. Acute myocardial infarction is one of the leading causes of mortality and morbidity, both in rural and urban area.
This study aims to investigate and evaluate clinical performance and quality measures for adults with acute ST-elevation myocardial infarction (STEMI) in China. Further more, the investigates like to develop quality improvement strategies and relevant tools focusing on treatment and clinical outcome in patients with STEMI.
This is a annually survey , through consecutively recruiting all eligible inpatients and collecting relevant medical information, the performance of all participating hospitals. Demographic characteristics, clinical features, diagnostic tests, medications, procedures, and in-hospital outcomes of patients will be obtained and then, the treatment pattern and outcomes will be evaluated. Further, quality improvement strategies including summary of clinical performance and quality measures, clinical pathways and professional training will be organized for the purpose of quality improvement. All hospitals will consecutively recruit qualified patients in the same method adopted in baseline period. Then the reperfusion rates and other performance measures will be compared annually.
New knowledge will be generated about STEMI management in China, to improve STEMI patients prognosis in future.
Interventions
- Behavioral Quality improvement strategies and tools
Quality improvement strategies and tools
Primary outcome measures
- Aspirin at arrival [Time frame: 24 hours after admission]
- Clopidogrel (or ticagrelor) at arrival [Time frame: 24 hours after admission]
- β-blockers at arrival [Time frame: 24 hours after admission]
- ECG at arrival [Time frame: 24 hours after admission]
- Reperfusion therapy rate [Time frame: 24 hours after admission]
- Time delay from failure of fibrinolysis to angiography(The time from start of fibrinolysis to evaluation of its efficacy is 60-90min) [Time frame: 10 days on average (during hospitalization)]
- Time delay from start of fibrinolysis to angiography(if fibrinolysis is successful) [Time frame: 10 days on average (during hospitalization)]
- Timeliness of thrombolytic therapy [Time frame: 24 hours after admission]
- Timeliness of primary PCI [Time frame: 24 hours after admission]
- Door-in-Door-Out Time [Time frame: 24 hours after admission]
Eligibility criteria
Inclusion criteria
- Patients with STEMI who arrive at the hospital within 48 hours from the symptoms onset.
Exclusion criteria
- None
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
China · 1 center
- Hongjian Wang — Beijing
Identifiers
NCT: NCT04088682 · NCCQI-CAD